Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age - GuruFocus.com

Value Investing | Market insights and news of the investment gurus. Value investing screens and valuation tools.

• In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 Vaccine elicited a strong immune response in this age group
• Three 3-µg doses had favorable safety profile similar to place… [+30840 chars]
  full article...